Editorial: Biological drugs and biosimilars in autoimmune diseases.
作者信息
Wajda Anna, Perricone Carlo, Kashyap Anniruddh, Iliyasu Mahmud Yerima
机构信息
Department of Molecular Biology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
出版信息
Front Pharmacol. 2023 Mar 2;14:1168972. doi: 10.3389/fphar.2023.1168972. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Biological drugs and biosimilars in autoimmune diseases.社论：自身免疫性疾病中的生物药物和生物类似药
Front Pharmacol. 2023 Mar 2;14:1168972. doi: 10.3389/fphar.2023.1168972. eCollection 2023.
2
Use of Biologics and Biosimilars in Rheumatology.生物制剂和生物类似药在风湿病学中的应用。
J Assoc Physicians India. 2017 May;65(5 Suppl):9-14.
3
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.风湿病学中生物类似药疗法及生物制品预期仿制药的临床与监管视角
Rheumatol Int. 2016 May;36(5):613-25. doi: 10.1007/s00296-016-3444-0. Epub 2016 Feb 27.
4
Update on biosimilars in rheumatology.风湿病学中生物类似药的最新进展。
Inflammopharmacology. 2017 Apr;25(2):177-184. doi: 10.1007/s10787-017-0333-4. Epub 2017 Mar 7.
5
Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know.初级保健中的免疫介导的慢性疾病的生物类似药：执业医师需要了解的内容。
Am J Med Sci. 2018 May;355(5):411-417. doi: 10.1016/j.amjms.2017.12.014. Epub 2017 Dec 29.
6
Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.生物制剂（包括生物类似药）的安全性：现状与未来方向的视角。
Drug Saf. 2018 Nov;41(11):1013-1022. doi: 10.1007/s40264-018-0684-9.
7
Biosimilars in pediatric rheumatology and their introduction into routine care.儿科风湿病学中的生物类似药及其在常规护理中的应用。
Clin Immunol. 2020 Jul;216:108447. doi: 10.1016/j.clim.2020.108447. Epub 2020 May 1.
8
Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.英夫利昔单抗和依那西普原研药与相应生物类似药治疗保留率：北欧协作观察性研究 2334 例生物制剂初治的脊柱关节炎患者。
RMD Open. 2019 Oct 23;5(2):e001079. doi: 10.1136/rmdopen-2019-001079. eCollection 2019.
9
[The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].[波兰特别工作组关于单克隆抗体和可溶性受体生物治疗安全性的立场声明]
Pol Merkur Lekarski. 2014 Jul;37(217):5-9.
10
A bio-what? Medical companions' perceptions towards biosimilars and information needs in rheumatology.生物制剂是什么？风湿病领域医疗伙伴对生物类似药的认知及信息需求。
Rheumatol Int. 2022 Nov;42(11):1993-2002. doi: 10.1007/s00296-021-05037-5. Epub 2021 Oct 27.
引用本文的文献
1
Inflammation: The Cause of All Diseases.炎症：百病之源。
Cells. 2024 Nov 18;13(22):1906. doi: 10.3390/cells13221906.
本文引用的文献
1
Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis.类风湿关节炎和银屑病关节炎治疗中的药物相互作用。
Rheumatol Int. 2020 Apr;40(4):511-521. doi: 10.1007/s00296-020-04526-3. Epub 2020 Feb 12.
2
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.用抗肿瘤坏死因子α嵌合单克隆抗体治疗类风湿性关节炎。
Arthritis Rheum. 1993 Dec;36(12):1681-90. doi: 10.1002/art.1780361206.
Zotero 插件